Management

Mr. Lakey is President and Chief Executive Officer and a member of the Board of Directors. Mr. Lakey joined Orion when it was founded as Vice President of Technology Operations and has served as President and Chief Executive Officer since June 2000. Mr. Lakey has 17 years of experience in genomics. Prior to coming to Orion Genomics, he was Director of DNA Sequencing at Millennium Pharmaceuticals, Inc., in Cambridge, Massachusetts (1994-98). There, he established and managed Millennium's large-scale sequencing department, and participated in strategic planning and business development efforts. Mr. Lakey's implementation of DNA sequencing quickly became fundamental to Millennium's technology platform. Before joining Millennium, Mr. Lakey worked as a Research Associate with Dr. George Church at Harvard Medical School's Department of Genetics where he focused on technology development for the Human Genome Project. Mr. Lakey received his B.A. in Biochemistry from the University of Texas (Austin).

Ms. Johns is internal Counsel for Orion. Prior to joining Orion Genomics in September 2002, she held an associate position at Suelthaus & Walsh, PC, specializing in intellectual property protection and licensing. Ms. Johns received her B.S. in Engineering Science with a minor in chemistry from the School of Engineering at Vanderbilt University and received a J.D. from Saint Louis University School of Law, where she received academic honors in patent law. She is admitted to practice law in Missouri and Tennessee and is registered to practice before the United States Patent and Trademark Office.

Dr. McPherson is Acting Vice President of Research and Development. Dr. McPherson is a member of the Board of Directors, and is a scientific co-founder of the Company. He is currently the Cancer Genomics Director at the Ontario Institute for Cancer Research and is focusing on genomic and proteomic characterization of cancer stem cells for biomarker discovery for improved imaging and diagnostic and treatment potential. Previously, he was Associate Professor of Molecular and Human Genetics at Baylor College of Medicine and faculty member of the Human Genome Sequencing Center (2003-2007) where his research focused on utilizing high-throughput genomic resources to study human disease and functional genomics. Dr. McPherson's prior appointments were Associate Professor of Genetics and Co-Director of the Genome Sequencing Center at Washington University School of Medicine, St. Louis, Missouri (1995-2003) and Assistant Professor of Biological Chemistry and Co-Director of the Human Genome Research Center at the University of California at Irvine (1994-1995). Dr. McPherson is an expert in physical mapping and positional cloning and played a lead role in the generation of the human and mouse physical maps as part of the Human Genome Project. Dr. McPherson received his B.S. and Ph.D. in Biochemistry from Queen's University (Ontario) and was a Postdoctoral Fellow in the Biochemistry Department at the University of California (Irvine).

Jared Ordway, Ph.D. is Director of Research and Development at Orion Genomics. Since joining Orion in 2004, he has participated in the development and validation of a novel comprehensive DNA methylation profiling technology and has applied this technology to the successful discovery of powerful DNA methylation-based biomarkers for various cancers. Dr. Ordway received his Ph.D. in Biochemistry and Molecular Genetics from the University of Alabama at Birmingham where his work was focused on the development and characterization of gene-targeted mouse models of neurodegenerative diseases caused by CAG repeat expansion mutations, including Huntington's Disease, Kennedy's Disease, and the spinocerebellar ataxias. He completed his Postdoctoral Fellowship in the laboratory of Dr. Tom Curran at St. Jude Children's Research Hospital where his research focused on the role of DNA methylation in oncogenic transformation and brain tumorigenesis.